THURSDAY, Feb. 7 (HealthDay News) -- A number of markers of the epithelial to mesenchymal transition and tumor invasion decrease after treating non-small cell lung cancer patients with celecoxib and erlotinib, researchers report in the February issue of the Journal of Thoracic Oncology.
Karen L. Reckamp, M.D., from the City of Hope and Beckman Research Institute in Duarte, Calif., and colleagues measured the levels of serum soluble E-cadherin, matrix metalloproteinase-9 (MMP-9), tissue inhibitor of MMP-1 (TIMP-1) and the chemokine CCL15 in 22 patients with non-small cell lung cancer treated with celecoxib and erlotinib.
After eight weeks of treatment, the researchers found a significant decrease in soluble E-cadherin, TIMP-1 and CCL15 levels in patients who partially responded to treatment. Baseline MMP-9 was also significantly lower in patients who responded to treatment.
"Soluble E-cadherin, MMP-9, TIMP-1 and CCL15 correlate with response to combination therapy with erlotinib and celecoxib in patients with non-small cell lung cancer," Reckamp and colleagues conclude.
Abstract
Full Text (subscription or payment may be required)
